A b s t r a c t
Introduction
Coronary heart disease (CHD) is the leading cause of mortality worldwide, claiming 587 000 lives per year [1, 2] . The cardinal mechanism of CHD is progressive atherosclerosis. Various signaling molecules such as proinflammatory cytokines (e.g., high-sensitivity C-reactive protein, tumor necrosis factors, and soluble adhesion molecules), matrix metalloproteinase and growth factors have been implicated in the process of atherosclerosis [3, 4] . Recently, pregnancy-associated plasma protein A (PAPP-A), a newly discovered zinc-binding metalloprotein, has received considerable interest [5] . Clinical studies have reported that elevated plasma PAPP-A was a sensitive, specific and early biomarker for the diagnosis of acute coronary syndrome (ACS) [6] [7] [8] . Furthermore, prospective trials have reported that elevated PAPP-A was an independent risk factor for adverse vascular events [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Therefore, identifying this new biomarker could be helpful to improve diagnostic and therapeutic decision-making.
The PAPP-A primarily acts as a protease cleaving inhibitory binding proteins of insulin-like growth factors [25] [26] [27] . In vitro studies have found that PAPP-A is mainly secreted by coronary artery smooth muscle cells under the stimulation of proinflammatory cytokines. Activation of the nuclear factor-κB pathway seems to be involved [28, 29] . What is more, PAPP-A is not just a biomarker. Animal studies have shown that PAPP-A plays an important role in advanced atherosclerosis. An animal model with a PAPP-A knock-out gene could resist the progression of atherosclerosis, whereas an animal model with overexpression of PAPP-A had accelerated progression of atherosclerosis [26, [30] [31] [32] . Accumulating clinical evidence has suggested that PAPP-A is a prognostic indicator for adverse vascular events for CHD patients. However, these results are inconsistent. Some studies have reported that serum elevated PAPP-A is associated with adverse vascular outcomes, while others reported a null association [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . So it remains uncertain whether elevated serum PAPP-A level is an independent risk factor for CHD. Therefore, we performed a meta-analysis to assess the association between elevated serum PAPP-A and relevant vascular events in patients with CHD.
Material and methods

S Se ea ar rc ch h s st tr ra at te eg gy y
We performed this meta-analysis according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [33] . Two authors (Yuehua Li and Chenghui Zhou) identified articles through search of MEDLINE (PubMed) from 2000 to Feb 2013. The key word used in the search was "PAPP-A". No language restriction was applied for searching and study inclusion.
S St tu ud dy y s se el le ec ct ti io on n
The inclusion criteria were determined as follows: (i) prospective study design; (ii) provide referent (lowest) and highest levels of serum PAPP-A; (iii) provide multivariable adjusted relative risks (RRs) and their corresponding 95% confidence intervals (CIs).
O Ou ut tc co om me es s
The primary outcome was all-cause mortality. The secondary outcomes included combination of all-cause mortality and non-fatal myocardial infarction (MI), and combined cardiovascular events (cardiac death, MI or revascularization).
D
Da at ta a e ex xt tr ra ac ct ti io on n Data extraction was conducted by two independent authors (Yuehua Li and Chenghui Zhou). Discrepancies were resolved by group discussion. We did not contact the authors of the original studies for missing data. The extracted data included first author's name, publication year, sample size, number of events, male proportion, mean age, duration of follow-up, assay methods for measuring PAPP-A, cut-off value of PAPP-A, adjusted covariates and RRs and their corresponding 95% CIs. We extracted RRs from the most fully adjusted model for the highest levels of PAPP-A compared with the lowest ones.
S St ta at ti is st ti ic ca al l a an na al ly ys si is s
We considered the hazard ratio or odds ratio as RRs in the prospective studies. Compared with the lowest category of PAPP-A, the pooled RRs and their 95% CIs were estimated by a random-effects model to incorporate the inter-study variability [34] . The heterogeneity was assessed by the Q statistic, I 2 and p value. We tried to explore the potential sources of heterogeneity by subgroup analysis according to follow-up term, assay methods of measuring PAPP-A, and different types of CHD patients (patients with stable CHD, suspected or established ACS). The pointof-care (POC) time-resolved immunofluorometric assay could also be a kit which is based on a comparable strategy like an enzyme-linked immunosorbent assay (ELISA) kit. Therefore, assay methods were classified by ELISA or POC assay and other methods. We also performed sensitivity analysis by excluding studies which provided the RRs with less than 5 adjusted variables.
We assessed publication bias by Begg's funnel plot and Egger's regression test [35] . Two-sided p value < 0.05 was considered to be significant. All of these analyses were completed by using STATA software (10.0 version, Stata Corporation, TX, USA).
Results
S
Se ea ar rc ch h r re es su ul lt ts s
We identified 1337 articles in the initial search. Of those studies, 1291 citations were excluded based on titles and abstracts due to experimental studies, reviews, or non-relevant. Forty-six potential articles were selected for the detailed assessment. We further excluded 32 ones for the following reasons: cross-sectional design (n = 18), not providing the needed endpoints (n = 10), comment or review (n = 2), not providing the multivariable adjusted RRs (n = 2). The study of Iversion et al. [14] was divided into two cohorts because they provided separated data for patients with ST-segment elevated myocardial infarction and non-ST-segment elevated ACS, respectively. Finally, 14 prospective studies (15 independent cohorts) concerning 12 830 participants and 1813 cases were included in our meta-analysis [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [23] . Of the 15 cohorts, there were 7 endpoints of all-cause mortality [11, 12, [14] [15] [16] [17] 23] , 7 combinations of all-cause mortality and non-fatal MI [12-16, 20, 22] , and 4 combinations of cardiac death, MI or revascularization [9, 10, 19, 21] .
S St tu ud dy y c ch ha ar ra ac ct te er ri is st ti ic cs s
The characteristics of 14 included studies are presented in Table I . Ten were conducted in Europe [10, 11, 13-16, 19, 20, 22, 23] , two in the United States [9, 12] , one in Canada [17] , and one in Asia [21] . The sample size ranged from 129 to 3782, the average age from 52 years to 70.5 years, and the followup term from 6 months to 8.8 years. Serum PAPP-A was measured by ELISA or POC assay in 11 studies [9] [10] [11] [12] [14] [15] [16] [17] [18] [19] [20] [21] , others in 3 studies [13, 22, 23] . The cutoff value of serum PAPP-A was derived from the median in 2 studies [17, 23] , others in 12 studies [9] [10] [11] [12] [13] [14] [15] [16] [19] [20] [21] [22] .
M Ma ai in n a an na al ly ys si is s
Compared with the lowest levels, the pooled RR for all-cause mortality was 1.78 (95% CI: 1.33 to 2.40, p < 0.001; I 2 = 42.8%, p for heterogeneity = 0.106) (Figure 1 A) ; for combined all-cause mortality and non-fatal MI it was 1.75 (95% CI: 1.36 to 2.26, p < 0.001; I 2 = 49.3%, p for heterogeneity = 0.066) (Figure 1 B) ; for combined cardiovascular events it was 1.58 (95% CI: 1.19 to 2.11, p < 0.00; I 2 = 20.9%, p for heterogeneity = 0.285) (Figure 1 C) for high elevated PAPP-A. Table II shows the subgroup analyses. For the endpoint of all-cause mortality, duration of followup and different type of CHD (stable CHD or ACS) did not modify the positive association of elevated PAPP-A with all-cause mortality. Six studies [11, 12, [14] [15] [16] [17] detected serum PAPP-A in ELISA and one study [23] used one-step enzyme immunoassay, so we did not perform the subgroup analysis by different assay methods. For the endpoint of combined all-cause mortality and non-fatal MI, duration of follow-up, different assay methods of measuring PAPP-A and different type of CHD were not modifiable factors.
Two studies provided RR with less than five adjusted variables [17, 21] . Sensitivity analyses showed that, when excluding the study of Kavsak et al. [17] , the pooled RR for mortality is 1.75 (95% CI 1.25 to 2.44; p = 0.001); when excluding the study of Mei et al. [21] , the pooled RR for cardiovascular events is 1.46 (95% CI 1.18 to 1.81; p = 0.000).
P Pu ub bl li ic ca at ti io on n b bi ia as s
No evidence of publication bias was observed in Begg's funnel plot. The results were further confirmed in Begg's adjusted rank correlation test (p = 0.18, p = 0.10,) and Egger's regression test (p = 0.16, p = 0.56) for the association of serum elevated PAPP-A with all-cause mortality, and combined all-cause mortality and non-fatal MI ( Figures  2 A and 2 B) .
Discussion
In our meta-analysis of 14 prospective studies, we observed that circulating elevated PAPP-A predicts adverse vascular events in patients with CHD. Patients with elevated PAPP-A were associated with a 1.78-fold higher risk for all-cause mortality, 1.75-fold for combined all-cause mortality and MI, and 1.58-fold for combined cardiovascular events (including cardiac death, myocardial infarction or revascularization). The positive association between elevated PAPP-A and adverse vascular events was not modified by duration of follow-up, different methods for measuring PAPP-A and different type of CHD.
Whether PAPP-A is an independent predictor for adverse vascular events is controversial. Several clinical trials have reported a positive relationship while others did not. Almost all the included studies have controlled for established cardiovascular risk factors or prognostic indicators, such as age, gender, hyperlipidemia, hypertension, diabetes, smoking, history of CHD, left ventricular ejection fraction, troponin, inflammatory markers, and so on [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [23] . We combined all these studies and found that serum PAPP-A is an independent risk factor for patients with CHD. Furthermore, our sensitivity analyses showed consistent results when we excluded the studies with less than 5 adjusted variables [17, 21] . So the results of our meta-analysis indicated that elevated PAPP-A was an independent risk factor for adverse vascular events for CHD patients.
Heterogeneity is often a concern of a metaanalysis. Different studies have been performed in different types of patients (e.g., patients with stable CHD, ACS, or suspected ACS), with different duration of follow-up, so the included trials were varied with different cut-off values of PAPP-A even under the same assay methods [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, our subgroup analyses found that patient type, follow-up term and assay methods of serum PAPP-A 
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Yuehua Pregnancy-associated plasma protein A predicts adverse vascular events in patients with coronary heart disease: a systematic review and meta-analysis were not factors modifying the results. Nevertheless, the cut-off value of PAPP-A in CHD patients and the potential modifying factors require further exploration in larger prospective studies.
Several mechanisms may be involved in the probability of elevated PAPP-A in predicting adverse vascular events in CHD patients. First, PAPP-A is not only a biomarker of ACS but also plays an important role in atherosclerosis [31, 36] . Animal studies have demonstrated that PAPP-A knock-out mice could resist progression of atherosclerosis [26] . Vice versa, over-expression of the PAPP-A gene in a mouse model of atherosclerosis could accelerate the development of atherosclerosis [32] . In addition, PAPP-A knock-out mice could resist proliferation and migration of vascular smooth muscle cells. Vascular smooth muscle cells are the major cells which lead to restenosis and fatal events after the first ACS [37] . So it seemed plausible that elevated PAPP-A levels could predict restenosis or subsequent vascular events. Second, circulating PAPP-A is related to the extent of atherosclerosis. Clinical studies have reported that patients with complex stenosis have higher levels of PAPP-A than ones with smooth stenosis [38, 39] . Therefore, patients with higher PAPP-A levels may be at higher risk for vascular events. Third, various studies have demonstrated that PAPP-A is positively correlated with local inflammation, which was a well-established risk factor for prognosis of CHD patients [29, 36, 40] . So PAPP-A may also be useful in improving risk stratification for CHD patients [41] [42] [43] . Finally, in our meta-analysis, we found that an elevated PAPP-A level seemed to be more associated with all-cause mortality or combined all-cause mortality and nonfatal MI than combined cardiovascular events. The possible explanation was that PAPP-A is not only a cardiac biomarker, but also a non-cardiac biomarker [44] . Recent studies have found that PAPP-A is also an biomarker associated with malignant cancer and end-stage renal disease [45, 46] . So patients with an elevated PAPP-A level not only have a high risk of cardiovascular events, but also have a higher risk of death.
Our study has several strengths. The major strength is that all of the included studies are of prospective design, which eliminates revision bias and minimizes selection bias. Furthermore, we performed a series of subgroup and sensitivity analyses to explore potential sources of heterogeneity. The consistent results from subgroup and sensitivity analyses have strengthened the statistical power.
Our study also has a few limitations. First, the residual confounders may be potential limitations. Most included studies have adjusted a wide range of potential confounders. However, we cannot exclude the potential influence of unadjusted variables on the results. Second, the predictive value of circulating PAPP-A in CHD patients may be affected by study design. However, we did not find that the predictive value of PAPP-A varied by short or long follow-up term, stable CHD or ACS, or different assay measurements. Third, all of the included studies are varied with different cut-off values of PAPP-A. Given the nature of a meta-analysis, we could not provide the cut-off value of serum PAPP-A. Finally, potential publication bias might influence the results; however, we found no evidence of publication bias.
In conclusion, elevated serum PAPP-A level is associated with adverse vascular outcomes in patients with CHD. The independent predictive value of PAPP-A was not affected by follow-up term, assay methods, or types of CHD. Further studies should test the newly defined cut-off value of elevated PAPP-A and put PAPP-A in use from bench to bedside.
